We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-12.34%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$111M
AUM Growth
+$65.4M
(+145%)
Cap. Flow
+$21.2M
Cap. Flow
% of AUM
19.2%
Top 10 Holdings %
Top 10 Hldgs %
96.91%
Holding
38
New
10
Increased
9
Reduced
4
Closed
15
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
1.1
quarters
Top 20 Avg Time Held Equity + Options
2.1
quarters
Avg Time Held Equity only
1.3
quarters
Top 10 Avg Time Held Equity only
0.2
quarters
Top 20 Avg Time Held Equity only
0.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Paranovus Entertainment Technology
PAVS
|
+$8.07M |
| 2 |
TOYO Co
TOYO
|
+$6.19M |
| 3 |
Farmmi Inc
FAMI
|
+$4.28M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$2.01M |
| 5 |
CervoMed
CRVO
|
+$877K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALP
Alpha Compute
ALP
|
+$655K |
| 2 |
Big Tree Cloud Holdings
DSY
|
+$337K |
| 3 |
TuanChe
TC
|
+$242K |
| 4 |
Pop Culture Group
CPOP
|
+$201K |
| 5 |
InMed Pharmaceuticals
INM
|
+$194K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 93% |
| 2 | Technology | 3.17% |
| 3 | Healthcare | 2.02% |
| 4 | Consumer Staples | 1.27% |
| 5 | Utilities | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Bluejay Diagnostics
BJDX
$820K
| – | – |
-28,726
| Closed | -$52.9K | – |
|
27
Can-Fite BioPharma American Depositary Shares
CANF
$4.18M
| – | – |
-42,559
| Closed | -$132K | – |
|
28
Calidi Biotherapeutics
CLDI
$2.45M
| – | – |
-27,181
| Closed | -$104K | – |
|
|
29
Pop Culture Group
CPOP
$3M
| – | – |
-4,430
| Closed | -$201K | – |
|
30
PUT
Gevo
GEVO
$316M
| – | – |
-5,252
| Closed | -$1.43M | – |
|
31
DELISTED
LYRA THERAPEUTICS INC
LYRA
| – | – |
-104,059
| Closed | -$51.1K | – |
|
32
Moleculin Biotech
MBRX
$8.44M
| – | – |
-75,021
| Closed | -$172K | – |
|
|
ALP
33
Alpha Compute
ALP
$5.89M
| – | – |
-41,442
| Closed | -$655K | – |
|
34
Arcadia Biosciences
RKDA
$544K
| – | – |
-114,554
| Closed | -$158K | – |
|
35
China SXT Pharmaceuticals
SXTC
$135K
| – | – |
-977
| Closed | -$131K | – |
|
|
36
TuanChe
TC
$38.6M
| – | – |
-23,239
| Closed | -$242K | – |
|
37
TRX Gold Corp
TRX
$377M
| – | – |
-100,000
| Closed | -$150K | – |
|
|
38
Big Tree Cloud Holdings
DSY
$16M
| – | – |
-137,611
| Closed | -$337K | – |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2026 Portfolio in Review
As of Q2 2026, Sabby Management held 38 positions worth $111M, up 145% from $45.1M the previous quarter. Its ten largest holdings account for 97% of the portfolio.
Sabby Management deployed $21.2M of net new capital in Q2 2026, opening 10 new positions and adding to 9 existing holdings. Its largest new stake was Paranovus Entertainment Technology: 75,440 shares worth $561K.
By sector, the portfolio is most concentrated in Miscellaneous at 93% of assets, up from 92% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was InMed Pharmaceuticals, an estimated $194K trimmed.
- Sabby Management's largest Q2 2026 buy was Paranovus Entertainment Technology: 75,440 shares worth $561K.
- Sabby Management added most to State Street SPDR S&P 500 ETF Trust in Q2 2026, an estimated $2.01M increase.
- Sabby Management's biggest Q2 2026 reduction was InMed Pharmaceuticals, cutting an estimated $194K.
- Sabby Management fully exited Alpha Compute in Q2 2026, selling an estimated $655K.
- Sabby Management's ten largest holdings make up 97% of its $111M portfolio in Q2 2026.
- Sabby Management opened 10 new positions and closed 15 in Q2 2026.
- Sabby Management's portfolio value rose 145% quarter-over-quarter to $111M.
Based on Sabby Management's 13F filing for Q2 2026, filed 14 Aug 2026.